According to the report, treatment with PCSK9 inhibitors generates cost-effectiveness ratios that exceed the commonly-accepted $100,000 per quality-adjusted life year (QALY).

For whichever PCSK9 we choose, we get an additional 50% to 60% LDL reduction by using these therapies. So, they work. They lower events. Both trials with PCSK9 inhibitors lowered events by about 15%.

The promise of a new era of cholesterol management, heralded by the launch of highly effective PCSK9 inhibitors, has been complicated by significant barriers to uptake of the next-generation products ...

In the last few years the PCSK9 inhibitors have been one of the few bright lights in an otherwise dismal field of new cardiovascular drugs. Now the FDA is raising questions that could dramatically ...

Between PCSK9 inhibitor and the time of the analysis, median total cholesterol fell from 210 mg/dL to 133 mg/dL, median LDL fell from 125 mg/dL to 53 mg/dL, median non-HDL fell from 158 mg/dL to ...

PCSK9 Mutations in Familial Hypercholesterolemia: from a Groundbreaking Discovery to Anti-PCSK9 Therapies Petra El Khoury Sandy Elbitar Marianne Abifadel Current Atherosclerosis Reports (2017) ...

Sanofi is pulling its PCSK9 drug Praluent from the Chinese market. President Donald Trump said U.S. pharmaceutical tariffs ...

A large case-control study using genetic proxies for PCSK9 inhibitors may help alleviate concerns that the dyslipidemia agents could promote adverse cardiac remodeling and heart failure.

The PCSK9 inhibitor market is projected to experience substantial growth due to its use in statin-intolerant patients, emerging strategies for PCSK9 inhibition, its potential applications across ...

MedCo. is a one-drug company whose lead asset, inclisiran, is one of several injectable, cholesterol-lowering meds known as PCSK9 inhibitors. And that’s a drug class with a checkered past. The two ...

PCSK9 was discovered in 2003. In 2003, researchers in France discovered PCSK9 while examining families with extremely high cholesterol and early heart attacks, according to the American Heart ...

The US Food and Drug Administration (FDA) has approved a label update for Swiss pharma giant Novartis’ Leqvio (inclisiran), ...